18F-FDG-PET and PET/CT for evaluating primary bone tumors

Erik Mittra, Andrei Iagaru

Research output: Contribution to journalArticle

Abstract

Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.

Original languageEnglish (US)
Pages (from-to)327-339
Number of pages13
JournalPET Clinics
Volume5
Issue number3
DOIs
StatePublished - Jan 1 2010
Externally publishedYes

Fingerprint

Fluorodeoxyglucose F18
bones
tumors
tomography
Tomography
Bone and Bones
Bone Diseases
Neoplasms
evaluation
disorders
Therapeutics

Keywords

  • Benign
  • Fluorodeoxyglucose
  • Malignant
  • Multiple myeloma
  • Positron emission tomography
  • Sarcoma

ASJC Scopus subject areas

  • Radiation
  • Radiology Nuclear Medicine and imaging

Cite this

18F-FDG-PET and PET/CT for evaluating primary bone tumors. / Mittra, Erik; Iagaru, Andrei.

In: PET Clinics, Vol. 5, No. 3, 01.01.2010, p. 327-339.

Research output: Contribution to journalArticle

Mittra, Erik ; Iagaru, Andrei. / 18F-FDG-PET and PET/CT for evaluating primary bone tumors. In: PET Clinics. 2010 ; Vol. 5, No. 3. pp. 327-339.
@article{7b276ee4ef57447ab1b1782af8013853,
title = "18F-FDG-PET and PET/CT for evaluating primary bone tumors",
abstract = "Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.",
keywords = "Benign, Fluorodeoxyglucose, Malignant, Multiple myeloma, Positron emission tomography, Sarcoma",
author = "Erik Mittra and Andrei Iagaru",
year = "2010",
month = "1",
day = "1",
doi = "10.1016/j.cpet.2010.04.004",
language = "English (US)",
volume = "5",
pages = "327--339",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - 18F-FDG-PET and PET/CT for evaluating primary bone tumors

AU - Mittra, Erik

AU - Iagaru, Andrei

PY - 2010/1/1

Y1 - 2010/1/1

N2 - Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.

AB - Imaging is critical for the proper evaluation of patients with primary tumors of bone. There is a growing role for 18F-fluorodeoxyglucose PET and PET/computed tomography (CT) in the grading, staging, prognostication, evaluation of therapeutic response, and detection of recurrent disease in bone. These modalities can also be used to help differentiate benign from malignant disorders of bone.

KW - Benign

KW - Fluorodeoxyglucose

KW - Malignant

KW - Multiple myeloma

KW - Positron emission tomography

KW - Sarcoma

UR - http://www.scopus.com/inward/record.url?scp=79954608966&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954608966&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2010.04.004

DO - 10.1016/j.cpet.2010.04.004

M3 - Article

VL - 5

SP - 327

EP - 339

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 3

ER -